Skip to main content
Premium Trial:

Request an Annual Quote

Perlegen Licenses Breast Cancer Markers from Cambridge University

NEW YORK (GenomeWeb News) - Perlegen Sciences said this week that it has licensed certain breast cancer biomarkers from Cambridge Enterprise Limited, the commercial arm of Cambridge University, and plans to commercialize the markers as a diagnostic test.
 
The agreement stems from a large-scale breast cancer study Perlegen, Cambridge, and Cancer Research UK began in 2005 that genotyped more than 50,000 women.
 
The study, published in Nature in June, identified certain breast cancer susceptibility markers that are present in roughly 20 percent of breast cancer cases in the UK. The company said this compares favorably to the BRCA1 and BRCA2 genes, which are used as diagnostic markers but occur in less than 5 percent of breast cancer cases.
 
The more common risk alleles identified in the Cambridge study “confer somewhat less overall risk than other described markers,” Perlegen said in a statement, but they double breast cancer risk in cases where there are two copies of the variants versus those with none.
 
Perlegen said it plans to market the diagnostic assay either directly or through a sub-license with a third party, and Cambridge University and partner Cancer Research Technology will receive a share of any financial returns, the company said.
 
Cambridge University reserves the right to provide non-commercial licenses to academic researchers.

The Scan

Study Tracks Off-Target Gene Edits Linked to Epigenetic Features

Using machine learning, researchers characterize in BMC Genomics the potential off-target effects of 19 computed or experimentally determined epigenetic features during CRISPR-Cas9 editing.

Coronary Artery Disease Risk Loci, Candidate Genes Identified in GWAS Meta-Analysis

A GWAS in Nature Genetics of nearly 1.4 million coronary artery disease cases and controls focused in on more than 200 candidate causal genes, including the cell motility-related myosin gene MYO9B.

Multiple Sclerosis Contributors Found in Proteome-Wide Association Study

With a combination of genome-wide association and brain proteome data, researchers in the Annals of Clinical and Translational Neurology tracked down dozens of potential multiple sclerosis risk proteins.

Quality Improvement Study Compares Molecular Tumor Boards, Central Consensus Recommendations

With 50 simulated cancer cases, researchers in JAMA Network Open compared molecular tumor board recommendations with central consensus plans at a dozen centers in Japan.